Product nameAPC Conjugation Kit - Lightning-Link®
APC Conjugation Kit / APC Labeling Kit (ab201807) uses a simple and quick process for APC labeling / conjugation of antibodies. It can also be used to conjugate other proteins or peptides. Learn about our antibody labeling kits and their advantages.
To conjugate an antibody to APC using this kit:
- add modifier to antibody and incubate for 3 hours
- add quencher and incubate for 30 mins
The APC conjugated antibody can be used immediately in WB, ELISA, IHC etc. No further purification is required and 100% of the antibody is recovered for use.
Learn about buffer compatibility below; for incompatible buffers and low antibody concentrations, use our rapid antibody purification and concentration kits. Use the FAQ to learn more about the technology, or about conjugating other proteins and peptides to APC.
Custom size conjugation kits up to 100 mg are available on demand. Please contact us to discuss your requirements.
This product is manufactured by Expedeon, an Abcam company, and was previously called Lightning-Link® APC Labeling Kit. 705-0015 is the same as the 1 mg size. 705-0010 is the same as the 3 x 100 ug size. 705-0030 is the same as the 3 x 10 ug size. 705-0005 is the same as the 100 µg size.
Amount and volume of antibody for conjugation to APC
Kit size Recommended
maximum amount of antibody
3 x 10 µg 3 x 10 µg 3 x 10 µL 100 µg 1x 100 µg 1 x 100 µL 3 x 100 µg 3 x 100 µg 3 x 100 µL 1 mg 1 x 1 mg 1 x 1 mL
1 Ideal antibody concentration is 1mg/ml. 0.5 - 1 mg/ml can be used if the maximum antibody volume is not exceeded. Antibodies > 1 mg/ml or < 0.5 mg/ml should be diluted /concentrated.
Buffer Requirements for Conjugation
Buffer should be pH 6.5-8.5.
Compatible buffer constituents
If a concentration is shown, then the constituent should be no more than the concentration shown. If several constituents are close to the limit of acceptable concentration, then this can inhibit conjugation.
50mM / 0.6% Tris1 0.1% BSA2 50% glycerol 0.1% sodium azide PBS Potassium phosphate Sodium chloride HEPES Sucrose Sodium citrate EDTA Trehalose
1 Tris buffered saline is almost always ≤ 50 mM / 0.6%
2 BSA can also interfere with the use of the conjugated antibody in tissue staining.
Incompatible buffer constituents
Thiomerosal Proclin Glycine Arginine Glutathione DTT
Only purified antibodies are suitable for use, ie. where other proteins, peptides, or amino acids are not present: antibodies in ascites fluid, serum or hybridoma culture media are incompatible.
Storing and handling conjugation kits
Lyophilized Lightning-Link® components are hygroscopic.
Kits are intentionally shipped at ambient temperature with silica gel to avoid exposure to moisture. Upon receipt, store the kit frozen and protect from moisture. Before opening the outer container, allow the lyophilized components to reach room temperature to minimize condensation.
Storage instructionsStore at -20°C. Please refer to protocols.
Components 100 µg 1 mg 3 x 10 µg 3 x 100 µg ab274126 - APC Conjugation Mix 1 x 100µg 1 x 1mg 3 x 10µg 3 x 100µg ab274106 - Modifier reagent 1 x 200µl 1 x 200µl 1 x 200µl 1 x 200µl ab274296 - Quencher reagent 1 x 200µl 1 x 200µl 1 x 200µl 1 x 200µl
Bouchery, Tiffany, et al used APC Conjugation Kit - Lightning-Link® (ab201807) as part of examining methods for arresting hookworm development. They used the kit to conjugate APC to anti-Na-APR-1 antibody for use with live hookworms in fluorescence microscopy.
Infective L3 stage hookworms were fed in vitro for 24 hr with RBC and treated with 10 μg of 11F3-APC monoclonal antibody against Na-APR-1 or with an isotype matched-RELM-APC control antibody. Larvae were allowed to empty their digestive contents for 2 hours in fresh DMEM before internal labelling was evaluated by confocal microscopy. Data representative of 50 larvae cultured in 3 independent experiments.
Haque, Nasreen S., Akaash Tuteja, and Niloufar Haque used APC Conjugation Kit - Lightning-Link® (ab201807) as part of examining as part of examining embryoid body formation. They used the kit to conjugate APC to anti-CCR8 antibody for use in immunofluorescence.
Anti CCL1 inhibits the expression of CCR8 and FoxP3 in mouse mesenchymal stem cells (mMSCs). Untreated (5a,-c) and anti-CCL1 treated (5d,-,f) cells were subjected to immunoflourescence with antibodies against FoxP3 (green;5b and e) or CCR8 (red;5c and f).
Dunne, Margaret R., et al used APC Conjugation Kit - Lightning-Link® (ab201807) as part of examining coeliac disease. They used the kit to conjugate APC to Vd3 antibody for use in flow cytometry.
Dotplots show flow cytometry data for representative control, treated and untreated coeliac donors.
Kim, Nayoung, et al used APC Conjugation Kit - Lightning-Link® (ab201807) as part of examining apoptosis in HIV-1-infected CD4+ primary T cells. They used the kit to conjugate APC to anti-pFOXO3a antibody for use in confocal microscopy.
Jurkat T cells expressing tTA alone, TatSF2+tTA, or TatSF2G48-R57A +tTA were stained with antibodies against PPP2R1B (first and forth columns of panels, green), pFOXO3a (second column, red), and FOXO3a (forth column, red).
Robinson, Andrew P., et al used APC Conjugation Kit - Lightning-Link® (ab201807) as part of characterizing oligodendroglial populations. They used the kit to conjugate APC to Mouse anti-O4 antibody, clone 81, for use in flow cytometry.
SJL/J mice were immunized with PLP139–151 and scored daily for clinical disease. A cohort of SJL/J mice was sacrificed, and spinal cords were analyzed by flow cytometry (n = 5). (A) Cells were distinguished from debris by forward and side scatter then singlet cells were gated. Live cells were gated by dead cell exclusion, and CNS resident cells were identified as CD45− or CD45low. (B) Oligodendroglial cells were defined by double positive staining: A2B5+PDGFRα+ early OPCs, A2B5+NG2+ intermediate OPCs, NG2+O4+ late OPCs, O4+MOG+ pre-myelinating oligodendrocytes, and GALC+MOG+ mature oligodendrocytes.
Drachsler, Moritz, et al used APC Conjugation Kit - Lightning-Link® (ab201807) as part of examining expression of CD95. They used the kit to conjugate APC to anti-human CD95 for use in flow cytometry.
The graph shows the CD95 expression in seven patient tumor samples.
Starkie DO et al. used ab201807 to identify antigen-specific mouse memory B cells from TNFR2 and IL-25 immunised mice.
McLinden RJ et al. used ab201807 as part of examining HIV-1 neutralizing antibodies.
They used the kit to conjugate APC to anti-human 4β7 antibody for use in flow cytometry.
A. Flow cytometric analysis of CD4, CCR5 and α4β7 expression in the A3R5.7 cell line. 0.5 x 106 cells were singly stained for 30 minutes with fluorochrome-conjugated antibodies as shown followed by fixation in 2% paraformaldehyde. Data are representative of at least two independent experiments. Isotype controls are shown in grey. Nearly all cells were positive for CD4 and CCR5 while approximately half were positive for α4β7.
B. Comparison of cell surface CD4, CCR5 and α4β7 receptor densities in various cell targets. 0.5 x 106 cells were stained with fluorochrome-conjugated antibodies and compared to defined populations of similarly stained Quantum Simply Cellular beads. PBMC were stimulated with CD3.8 bi-specific antibody in the presence of 50U/mL rhIL-2. Assuming monovalent antibody-to-surface receptor binding, the Antibody Binding Capacity (ABC) calculated is equivalent to receptors/cell. Data represents the mean of two separate experiments. TZM-bl cells express high levels of CD4 and CCR5 but are negative for α4β7 while A3R5.7 cells possess CCR5 and α4β7 densities more similar to PBMC. CD4 expression on TZM-bl was beyond assay range.
Del Cid N et al. used ab201807 as part of examining antigen cross-presentation.
They used the kit to conjugate APC to ovalbumin (OVA) and ovalbumin-calreticulin fusion protein (OVA-CRT) for use in in-gel fluorescence and flow cytometry.
OVA-CRT and OVA were labeled with allophycocyanin. (C) Labeling intensity was determined by fluorescence imaging of the proteins after separation by SDS-PAGE (inset). Fluorescence intensity was quantified for the indicated proteins. (D) Binding of fluorescent proteins to BMDC was assessed by flow cytometry. BMDC were incubated with labeled proteins on ice before being analyzed by flow cytometry. BMDC not incubated with proteins are depicted as a grey filled.
ab201807 has been referenced in 91 publications.
- Wheatley AK et al. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nat Commun 12:1162 (2021). PubMed: 33608522
- Nguyen THO et al. CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity. Immunity 54:1066-1082.e5 (2021). PubMed: 33951417
- Zheng H et al. Single B cells reveal the antibody responses of rhesus macaques immunized with an inactivated enterovirus D68 vaccine. Arch Virol N/A:N/A (2020). PubMed: 32462286
- Yang M et al. Optimizing TNFR2 antagonism for immunotherapy with tumor microenvironment specificity. J Leukoc Biol 107:971-980 (2020). PubMed: 32202358
- Benedicenti O et al. Type I Interferon Regulates the Survival and Functionality of B Cells in Rainbow Trout. Front Immunol 11:1494 (2020). PubMed: 32733485